Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 11:10:e10.
doi: 10.15420/cfr.2024.05. eCollection 2024.

Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life

Anastasia Shchendrygina  1 , Amina Rakisheva  2 , Ilya Giverts  3   4 , Yasmin Rustamova  5 , Anzhela Soloveva  6
Affiliations
Review

Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life

Anastasia Shchendrygina et al. Card Fail Rev. .

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity. Recently, GLP-1 RAs have garnered attention for their cardiovascular benefits beyond glycaemic control in patients with type 2 diabetes, exhibiting patterns previously seen in cardiovascular outcomes trials on sodium-glucose cotransporter 2 inhibitors, which now receive a high level of recommendation for the treatment of heart failure (HF). GLP-1 RAs have been increasingly investigated in HF cohorts, but mainly in small-scale studies reporting inconclusive findings regarding clinical outcomes and different safety profiles in HF patients with reduced and preserved ejection fractions. This review discusses the effects of GLP-1 RAs on surrogate HF outcomes, such as cardiac structure and function, exercise capacity and quality of life, in HF patients across the spectrum of left ventricular ejection fraction, to provide insights into the potential of these agents to be investigated in large clinical trials to evaluate clinical outcomes.

Keywords: Glucagon-like peptide-1 receptor agonists; cardiac function; exercise capacity; heart failure; quality of life.

PubMed Disclaimer

Conflict of interest statement

Disclosure: AR reports receiving speaker fees from Novartis, Roche Diagnostics and AstraZeneca, and is on the Cardiac Failure Review editorial board; this did not influence peer review. A Soloveva has received grants from the European Society of Cardiology and support from AstraZeneca, Bayer, Novartis and Servier. All other authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity, Quality of Life and Clinical Outcomes in Patients With Heart Failure
See this image and copyright information in PMC

References

    1. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57. doi: 10.1056/NEJMoa1509225. - DOI - PubMed
    1. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22. doi: 10.1056/NEJMoa1603827. - DOI - PMC - PubMed
    1. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44. doi: 10.1056/NEJMoa1607141. - DOI - PubMed
    1. Hernandez AF, Green JB, Janmohamed S et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–29. doi: 10.1016/S0140-6736(18)32261-X. - DOI - PubMed
    1. Holman RR, Bethel MA, Mentz RJ et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39. doi: 10.1056/NEJMoa1612917. - DOI - PMC - PubMed

LinkOut - more resources